


4/32 FIGURE 4 (A, B)








FIGURE 5 (A, B)




6/32


FIGURE 6 (a, b, c)



(a) 0 degree orientation of the PCL filament layer.




(b) 60 degree orientation of the PCL filament layer.




(c) 120 degree orientation of the PCL filament layer.


7/32 **FIGURE 7**



8/32


FIGURE 8 (A, B)






9/32


FIGURE 9 (A, B)



10/32 FIGURE 10



11/32



12/32





FIGURE 13




200x

in vitro culture 3ws




14/32 FIGURE 14 (A, B)



100x

(A)





200x

(B)

BEST AVAILABLE COPY

15/32 **FIGURE 15 (A, B)**






16/32

FIGURE 16 (A, B)




(A)




(B)

PCT/SG2004/000380 WO 2005/048885

17/32 **FIGURE 17 (A, B)**




5ws 100X (A)




(B)

















| | Marker Control | | | 20% TCP -PCL induction | | | | |
|-------------|---|--------------------------|---------|--|-------------|----------------------|------------|--------------------|
| | 100bp | 1w | lw | 3w | 4w | 5wy | 6w | 7 _W |
| Osterix | Contract Con | | | | | ignais daice. | | |
| Osteocalcin | | | | | eroza (a. c | enierie: | rice in | |
| Osteopontin | and the second second | and the second | | | | | ASSET ALSO | |
| Collagen I | | ないないない | | Carrier and Carrier (Carrier Carrier C | | -685.COTES: | | |
| Cbfa1 | | and design of the second | | | | eller berge | ia:we | AND THE CONTRACTOR |
| GAPDH | esessoer vibes | | na ries | | AVAL YES | REAL PROPERTY | | |




23/32




24/32



25/32 FIGURE 25 (A, B)





(A)




(B)


26/32 **FIGURE 26 (A, B)**







27/32 FIGURE 27 (A, B, C)








28/32




29/32

FIGURE 29 (A, B)




(A)



(B)

30/32



BEST AVAILABLE CO

31/32

FIGURE 30 (C)

(from Figure 30A)





(C)

PCT/SG2004/000380 WO 2005/048885

32/32

FIGURE 31 (A, B)

